Abstract
Bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, is conditionally approved in Europe for treatment of CHD, yet optimal treatment duration and the potential benefit of continued treatment...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
